FDA releases temporary guidance on production operations
The FDA has issued new temporary guidance that outlines the agency's recommendations for drug and biologics manufacturers as they prepare to return to normal operations for drug production amid the COVID-19 pandemic. The guidance also specifies areas where the FDA can judge when remediation is needed for some manufacturers. Regulatory Focus (9/11)
Read full article now.
Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!